A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Brentuximab vedotin (Primary) ; Lenalidomide (Primary)
- Indications Anaplastic large cell lymphoma; Cutaneous T cell lymphoma; Non-Hodgkin's lymphoma; T cell lymphoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.
- 15 Feb 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.